Streetbeat News

Analyst Ratings

CRMT

B of A Securities analyst John Murphy has maintained an Underperform rating on America's Car-Mart (NASDAQ:CRMT) and lowered the price target from $55 to $50.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:06 pm

KAR

B of A Securities analyst John Murphy upgraded Openlane (NYSE:KAR) from Underperform to Neutral and increased the price target from $16 to $20.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:05 pm

FHTX

Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $13 price target.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:04 pm

PAG

B of A Securities analyst John Murphy maintains a Buy rating on Penske Automotive Group (NYSE:PAG) and raises the price target from $175 to $180.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:03 pm

LAD

B of A Securities analyst John Murphy has maintained a Buy rating on Lithia Motors (NYSE:LAD) and increased the price target from $380 to $385.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:02 pm

CWK

Jefferies analyst Peter Abramowitz initiates coverage on Cushman & Wakefield (CWK) with a Buy rating and a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:02 pm

CBRE

Analyst ratings for CBRE Group (NYSE:CBRE) have varied over the past quarter, with a current average price target of $103.5, marking a 5.61% increase from the previous $98.00. Recent actions by analysts from Jefferies, Evercore ISI Group, Keefe, Bruyette & Woods, and Raymond James have adjusted ratings and price targets, reflecting changes in market conditions and company performance. CBRE Group's financials show strong growth, profitability, and efficient asset and equity management, with a revenue growth rate of 9.22% and a net margin of 5.33%.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 12:02 pm

AN

B of A Securities analyst John Murphy maintains a Buy rating on AutoNation (NYSE:AN) but lowers the price target from $220 to $215.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 12:01 pm

ATRC

AtriCure (NASDAQ:ATRC) has received updated analyst ratings, with a consensus indicating a bullish outlook. Over the past three months, four analysts have rated ATRC as bullish, with recent adjustments in price targets reflecting a slight decrease in the average target to $48.00 from $50.33. AtriCure's financial performance shows strong revenue growth and profitability, with a notable net margin and ROE. The company specializes in surgical treatments for atrial fibrillation and other related conditions, primarily serving the U.S. market.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 12:01 pm

EQT

Analyst opinions on EQT Corp (NYSE:EQT) over the past three months show a mix of bullish to bearish sentiments, with recent actions including both upgrades and downgrades in ratings and price targets. The average 12-month price target for EQT has decreased by 2.48% to $42.39. EQT's financial performance indicates challenges in revenue growth and asset utilization, but strong net margin and effective debt management. The company focuses on natural gas production in the Appalachian Basin.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 12:01 pm